High Quality High Purity Iopamidol Pharmaceutical Powder USP Standard CAS 60166-93-0

Superiority:

English name: Iopamidol

CAS number: 60166-93-0

Molecular formula: C17H22I3N3O8

Molecular weight: 777.09

EINECS Number: 262-093-6

Melting point:>3200C(dec)

Specific rotation: D20-2.01°(c=10inwater)

Boiling point: 740.14°C (rough estimate)

Density: 2.0203 (estimate)

Storage Conditions: Keep in dark place, Sealed in dry, 2-8°C

Iopamidol, also known as iodopeptidol, iodopentanol, iopamidol, iopamidol, iodobidol, iopamisone, is a non-ionic water-soluble contrast agent, which is a drug for imaging diagnosis. Its chemical structure is The amide compounds of triiodoisophthalic acid derivatives have low toxicity to blood vessel walls and nerves, good local and systemic tolerance, low osmotic pressure, low viscosity, good contrast, stable injection, and very little deiodination in vivo. Myelography and in patients with high risk factors for contrast reaction. After intravascular injection of iopamidol, it is mainly excreted through the kidneys. T1/2 varies with renal function, generally 2 to 4 hours, and is mainly excreted in the original form with urine, 90% to 95% is excreted in 7 to 8 hours, and almost 100% is excreted in 20 hours. In vivo, iopamidol is not metabolized, does not bind to plasma proteins, and does not interfere with isoenzymes. Due to the high content of iodine, this product attenuates X-rays to achieve the purpose of contrast imaging, and is suitable for X-ray contrast for intravascular injection. Iopamidol is clinically used for various angiography, such as cerebral arteriography. Cardiovascular angiography includes coronary arteries, thoracic and abdominal arteries, peripheral arteries, veins, and digital subtraction angiography. And urinary tract, joints, fistula, spinal cord, cistern and ventricle, selective visceral arteriography. Enhanced scan in CT examination.

1. Patients with severe arteriosclerosis, hypertensive heart failure, systemic diseases and those who have recently had cerebral thrombosis or embolism have an increased probability of complications. Chest tightness, bradycardia with decreased blood pressure, nausea, vomiting, dehydration, collapse, tinnitus, rash and sweating, and pain at the puncture site may be seen. Serious neurological complications occurred in individual cases. Very few have anaphylactic shock.

2. Disabled: Intrathecal injection is prohibited for patients with a history of epilepsy, Waldenstrom macroglobulinemia, multiple myeloma, severe liver and kidney disease, and local or systemic bacterial infection.

3. Use with caution: Intrathecal injection should be used with caution in patients with excessive activity or strain, bedridden inability to keep the head upright, intracranial hypertension or intracranial tumors, patients with blood abscesses, patients with a history of convulsions, patients with chronic alcoholism, and patients with multiple sclerosis. For patients with iodine allergy, allergic constitution, hyperthyroidism, spontaneous functional thyroid nodules, high-risk patients, the elderly and children, mild to moderate liver and renal insufficiency, cardiovascular disease, diabetes, history of asthma, and bloody cerebrospinal fluid. and patients with homozygous sickle cell disease, with or suspected cadmium pheocytoma, dysglobulinemia, homocystinuria, general anesthesia, congestive heart failure due to hypertonicity, chronic cardiovascular angiography Emphysema patients.

4. It is forbidden to be used in combination with other drugs. Co-administration with thioridazine increases the risk of cardiotoxicity, and co-administration of iopamidol and metformin produces lactic acidosis and can lead to acute renal failure.

5. Adverse reactions: The side effects of iopamidol are directly related to the concentration, dosage and mode of administration, and its osmotic pressure, viscosity and administration speed can all affect the incidence and severity of side effects. Headaches are common, and are frequently exacerbated by intrathecal administration in dehydrated patients. Mild toxic episodes are rare. Can cause dehydration, especially in elderly patients, patients with ammoniaemia, or debilitating patients may experience shock. In addition, dizziness, nausea, vomiting, mental symptoms, etc. can be seen.